Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kiadis Pharma has said that the FDA has approved company's investigational new drug application to allow the start of a clinical phase III study for its product Reviroc in the US.
Subscribe to our email newsletter
Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. This approval follows the successful end of phase II meeting with the FDA for Reviroc and the subsequent submission of the IND package to the FDA.